Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Myriam Chalabi*, Lorenzo F. Fanchi, Krijn K. Dijkstra, Jose G. van den Berg, Arend G. Aalbers, Karolina Sikorska, Marta Lopez-Yurda, Cecile Grootscholten, Geerard L. Beets, Petur Snaebjornsson, Monique Maas, Marjolijn Mertz, Vivien Veninga, Gergana Bounova, Annegien Broeks, Regina G. Beets-Tan, Thomas R. de Wijkerslooth, Anja U. van Lent, Hendrik A. Marsman, Elvira NuijtenNiels F. Kok, Maria Kuiper, Wieke H. Verbeek, Marleen Kok, Monique E. Van Leerdam, Ton N. Schumacher, Emile E. Voest*, John B. Haanen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)566-576
Number of pages21
JournalNature Medicine
Volume26
Issue number4
DOIs
Publication statusPublished - Apr 2020

Keywords

  • DNA MISMATCH REPAIR
  • COLORECTAL-CANCER
  • PD-1 BLOCKADE
  • GENERATION
  • TUMORS
  • NIVOLUMAB
  • SURVIVAL
  • THERAPY
  • EVASION
  • CELLS

Cite this